1. Pink Sheet
  2. >>Geography

Zolgensma ‘Lottery’ Attacked From All Sides

Fears It Could Damage Pharma Industry’s Reputation

 
• By Francesca Bruce

An unusual managed access program for Zolgensma designed by Novartis and AveXis has been attacked on ethical grounds, with critics claiming it does not properly allot the gene therapy to patients most in need. The companies have rejected the criticism, saying the program is fair and equitable.

Overcoming challenges and crisis . Mixed media
Novartis/AveXis Face Criticism Over Managed Access Program

Novartis/Avexis have come under fire from EU member states, patients and legal experts for their “lottery-style” managed access program (MAP) for the gene therapy for spinal muscular atrophy, Zolgensma. Critics have cited ethical concerns and claim the program is a reputational risk for the companies and the wider pharmaceutical industry.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

UK Mandates Unmodified Standardized Contracts To Speed Clinical Trial Set-Up

 
• By Vibha Sharma

The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

New EU Filings

 
• By Neena Brizmohun

Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.